Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with blinatumomab and other T cell-activating therapies develop cytokine release syndrome (CRS). We hypothesized that patients wi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Teachey, David T., Rheingold, Susan R., Maude, Shannon L., Zugmaier, Gerhard, Barrett, David M., Seif, Alix E., Nichols, Kim E., Suppa, Erica K., Kalos, Michael, Berg, Robert A., Fitzgerald, Julie C., Aplenc, Richard, Gore, Lia, Grupp, Stephan A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2013
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123427/
https://ncbi.nlm.nih.gov/pubmed/23678006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-02-485623
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki